{"id":192834,"date":"2026-11-03T12:59:10","date_gmt":"2026-11-03T11:59:10","guid":{"rendered":"https:\/\/test.lab.cor2ed.com\/cms\/?post_type=experts&#038;p=192834"},"modified":"2026-11-03T12:59:10","modified_gmt":"2026-11-03T11:59:10","slug":"dr-philippe-debonnaire-md-phd-fesc","status":"publish","type":"experts","link":"https:\/\/test.lab.cor2ed.com\/cms\/experts\/dr-philippe-debonnaire-md-phd-fesc\/","title":{"rendered":"Dr Philippe Debonnaire (MD, PhD, FESC)"},"content":{"rendered":"<p>Philippe Debonnaire (MD, PhD, FESC) graduated as cardiologist and obtained a Masters degree in Sports Medicine, both at Leuven University (Belgium).<\/p>\n<p>&nbsp;<\/p>\n<p>Subsequently, he obtained a PhD, based on non-invasive cardiac imaging research at Leiden University Medical Hospital (the Netherlands).\u00a0<\/p>\n<p>&nbsp;<\/p>\n<p>Since 2013 he works as cardiologist (interventional echocardiographist) in Sint-Jan Hospital Bruges (Belgium) with clinical and scientific focus on (advanced) echocardiographic techniques (3D, strain, stress, TOE).\u00a0<\/p>\n<p>&nbsp;<\/p>\n<p>Apart from valvular and structural heart disease, his current focus includes cardiac amyloidosis, with ongoing publications and lecturing on (inter)national podia.\u00a0<\/p>\n<p>&nbsp;<\/p>\n<p>He is immediate BWGNICI past-president, current EACVI Scientific Committee board member (former EACVI HIT and Education Committee positions), responsible for the echocardiography imaging fellowship in his centre.<\/p>\n","protected":false},"author":{"id":1337,"first_name":"Thais","last_name":"Miranda","nickname":"thais.miranda","email":"thais.miranda@cor2ed.com"},"featured_media":192836,"menu_order":0,"template":"","groups":[],"class_list":["post-192834","experts","type-experts","status-publish","has-post-thumbnail","hentry"],"expert_info_prefix":"Dr","expert_info_first-name":"Philippe","expert_info_last-name":"Debonnaire (MD, PhD, FESC)","expert_info_institution":"AZ Sint-Jan, Bruges","expert_info_country":"BE","expert_info_specialization":"Cardiologist","expert_info_map-code":"","expert_info_disclosures":"<p><b>Speaker\/consultancy fee: <\/b>AstraZeneca, Alnylam, Bayer, Pfizer<\/p>\r\n<p><b>Advisory board:\u00a0<\/b>AstraZeneca, Alnylam, Bayer, Pfizer<\/p>\r\n<p><b>Amyloid research grants: <\/b>AstraZeneca, Pfizer<\/p>\r\n<p><b>PI amyloid (randomised controlled) trials and studies: <\/b>Alexion \u2013 AstraZeneca Rare Disease, Alnylam, AstraZeneca, Bayer, BridgeBio, Bruges Cardiac Amyloidosis Registry, Eidos, ICAR,\u00a0Intellia Therapeutics,\u00a0Ionis, Novo Nordisk<\/p>","expert_info_linkedin":"","expert_info_twitter":"","expert_info_instagram":"","expert_info_facebook":"","_links":{"self":[{"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/experts\/192834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/experts"}],"about":[{"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/types\/experts"}],"version-history":[{"count":1,"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/experts\/192834\/revisions"}],"predecessor-version":[{"id":192837,"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/experts\/192834\/revisions\/192837"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/media\/192836"}],"wp:attachment":[{"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/media?parent=192834"}],"wp:term":[{"taxonomy":"groups","embeddable":true,"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/groups?post=192834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}